Bristol-Myers Squibb Company (BMY) Q4 2007 Earnings Results

Bristol Myers Squibb Misses on EPS — Stock Down 0.3%

Bristol Myers Squibb's earnings report showed a slight miss on EPS, which contributed to a small decline in the stock price. Investors may be concerned about the lack of guidance and the challenges mentioned by management. The company continues to focus on its drug pipeline, which could be crucial for future growth.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.33	N/A	-3.51%

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed a cautious outlook, emphasizing the importance of their drug pipeline. They acknowledged current market challenges but remain focused on future growth.

Management highlighted ongoing commitment to pipeline development.

They noted challenges in the current market environment but remain focused on long-term goals.

Bristol Myers Squibb Misses on EPS — Stock Down 0.3%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Misses on EPS — Stock Down 0.3%

Key numbers

Management commentary